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Objectives The purpose of this study was to compare health-related quality of life (HRQOL) outcomes in patients treated
with carotid artery stenting (CAS) versus carotid endarterectomy (CEA).
Background In CREST (Carotid Revascularization Endarterectomy versus Stenting Trial), the largest randomized trial of ca-
rotid revascularization to date, there was no significant difference in the primary composite endpoint, but rates
of stroke and myocardial infarction (MI) differed between CAS and CEA. To help guide individualized clinical deci-
sion making, we compared HRQOL among patients enrolled in the CREST study. We also performed exploratory
analyses to evaluate the association between periprocedural complications and HRQOL.
Methods We measured HRQOL at baseline, and after 2 weeks, 1 month, and 1 year among 2,502 patients randomly as-
signed to either CAS or CEA in the CREST study. The HRQOL was assessed using the Medical Outcomes Study
Short-Form 36 (SF-36) and 6 disease-specific scales designed to study HRQOL in patients undergoing carotid
revascularization.
Results At both 2 weeks and 1 month, CAS patients had better outcomes for multiple components of the SF-36, with
large differences for role physical function, pain, and the physical component summary scale (all p  0.01). On
the disease-specific scales, CAS patients reported less difficulty with driving, eating/swallowing, neck pain, and
headaches but more difficulty with walking and leg pain (all p  0.05). However, by 1 year, there were no differ-
ences in any HRQOL measure between CAS and CEA. In the exploratory analyses, periprocedural stroke was as-
sociated with poorer 1-year HRQOL across all SF-36 domains, but periprocedural MI or cranial nerve palsy were
not.
Conclusions Among patients undergoing carotid revascularization, CAS is associated with better HRQOL during the early recovery
period as compared with CEA—particularly with regard to physical limitations and pain—but these differences dimin-
ish over time and are not evident after 1 year. Although CAS and CEA are associated with similar overall HRQOL at
1 year, event-specific analyses confirm that stroke has a greater and more sustained impact on HRQOL than MI.
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plus medical management of
modifiable risk factors is an es-
tablished approach for primary
and secondary stroke prevention
for patients with significant ca-
rotid atherosclerosis (1–4). Some
patients, however, are considered
poor candidates for surgical re-
vascularization because of ana-
tomic complexity or medical co-
morbidities, and adverse outcomes
occur more frequently in these
patients (5). Carotid artery stent-
ing (CAS) was developed as a
less invasive option for carotid revascularization. The results
of clinical trials of CAS have varied, with several finding
acceptable rates of safety and efficacy (6–11), but others
reporting higher rates of adverse events as compared with
CEA (12–14).
See page 1566
The CREST (Carotid Revascularization Endarterectomy
versus Stenting Trial) recently compared CAS and CEA in
patients at low risk of surgical complications and found no
difference in the primary composite endpoint of stroke,
myocardial infarction (MI), or death during the periproce-
dural period, or ipsilateral stroke within 4 years (15).
Individual endpoints, however, varied between treatment
groups, with patients assigned to CAS having higher rates
of stroke and patients assigned to CEA having higher rates
of MI. These differences in risk of periprocedural stroke and
MI between the 2 treatment groups in the CREST study
have led to considerable debate regarding the optimal
treatment strategy for patients undergoing carotid revascu-
larization (16–19).
In light of this ongoing controversy, evaluation of health-
related quality of life (HRQOL) may help further inform
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ccepted May 24, 2011.individualized clinical decision making for patients under-
going carotid revascularization. Prior studies have suggested
less impairment during the early recovery period after CAS
as compared with CEA, but these differences were brief and
limited to highly sensitive, disease-specific outcomes and
physical role limitations (20,21). Moreover, these findings
were based on nonrandomized studies or small randomized
trials that enrolled highly selected patients. To address these
gaps in knowledge, we performed a prospectively planned
analysis of HRQOL among patients randomly assigned to
CAS or CEA in the CREST study. In addition, we
performed exploratory analyses to evaluate the association
between periprocedural complications and HRQOL during
1 year of follow-up.
Methods
Trial design. Details of the CREST study design and
primary outcomes have been described previously (15,22).
In brief, the CREST study was a randomized trial of CAS
versus CEA in both symptomatic and asymptomatic adult
patients with significant carotid stenosis by ultrasonography,
computed tomography, magnetic resonance imaging, or
conventional angiography. Exclusion criteria were prior
severe stroke, atrial fibrillation, unstable angina, or acute MI
within the past 30 days. Clinical and anatomical suitability
for either revascularization approach was required, after
which patients were enrolled and treated by certified oper-
ators (based on adequate procedural volume and low com-
plication rates) at 117 centers in the United States and
Canada (23).
Risk factor modification and aspirin were recommended
for all patients, and CEA was performed according to
published guidelines. Patients undergoing CAS received the
Rx Acculink stent and Rx Accunet embolic protection
device (Abbott Vascular Solutions, Santa Clara, California)
whenever feasible. Anticoagulation therapy was adminis-
tered according to local practice, and thienopyridine therapy
was recommended for a minimum of 4 weeks after the
procedure. Neurologic evaluation at scheduled intervals,
including the use of standardized stroke assessment mea-
sures, was performed in all patients. Cardiac biomarkers and
electrocardiograms were obtained in all patients before and
after the index procedure and after signs or symptoms of
cardiac ischemia. Approval was obtained from the Human
Studies Committee at each enrolling site, and all patients
provided written informed consent before participation.
Data definitions. The periprocedural period was defined as
the time from randomization through 30 days after revas-
cularization (or 36 days after randomization when the
procedure was not performed within 30 days of randomiza-
tion). Stroke was defined as an acute neurologic event with
focal findings consistent with cerebral ischemia that lasted
for 24 h or more. MI was defined as the presence of elevated
cardiac biomarkers at least twice the upper limit of normal
at the site’s hospital laboratory, plus either: 1) electrocardio-
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2) symptoms of a coronary event. Cranial nerve palsy was
defined as evidence of new cranial nerve injury on either the
post-procedure or 1-month neurologic assessment.
Health status assessment. The HRQOL was assessed
using standardized questionnaires at baseline, and at 2
weeks and 1 month after the procedure and 1 year after
randomization in all patients. The baseline and 1-year
questionnaires were administered in written fashion,
whereas the 2-week and 1-month assessments were per-
formed by telephone by a single, trained interviewer using
the same questionnaires. Overall health status was assessed
using the Medical Outcomes Study Short-Form 36 (SF-36)
(24). The SF-36 is a commonly used health survey that
assesses 8 dimensions of health status (physical functioning,
physical role limitations, bodily pain index, vitality, general
health, social functioning, emotional role limitations, and
mental health) and has been validated in patients with
cardiovascular disease, stroke, and in the general population
(24–27). Scores for the SF-36 range from 0 to 100, with
higher scores indicating better health status; a difference of
5 to 10 points is considered a clinically important change for
an individual subject (smaller differences may be important
for group comparisons) (28). In addition, the SF-36 pro-
vides summary scales for overall physical and mental health,
which are standardized to a population mean of 50 and a
standard deviation of 10, and for which individual differ-
ences of 2.5 to 5 points are considered clinically meaningful.
In addition to the SF-36, 6 disease-specific modified
Likert scales designed specifically for comparison of CAS
versus CEA were used to evaluate aspects of functional
status and symptoms that may be impacted by 1 or both of
the treatments (21,22). The first 3 questions assessed the
level of difficulty each patient experienced with walking,
eating/swallowing, and driving (1  no difficulty at all, 2 
mild difficulty, 3moderate difficulty, 4 severe difficulty,
5  unable to perform this activity). The next 3 questions
evaluated how often patients were bothered by headaches,
neck pain, and leg pain during the previous week (1  not
at all bothered, 2  bothered a little bit, 3  moderately
bothered, 4  bothered quite a bit, 5  extremely both-
ered). Two additional questions asked patients to rate their
level of pain (0 to 10 scale, in which 0  no pain and 10 
worst possible pain) and to estimate the number of times
pain medications were needed during the past week.
Statistical approach. All primary analyses of HRQOL
were performed on an intention-to-treat basis. Patients who
died during the study were included in the analyses of
HRQOL outcomes up until the time of death. Primary
findings were based on raw data, and sensitivity analyses
were performed using multiple imputation to estimate
missing HRQOL scores for surviving patients (29). Cova-
riates used in the multiple imputation models included all of
the available HRQOL scores, treatment assignment, and
baseline clinical and demographic characteristics. An on-
treatment analysis was also performed comparing patientswho underwent CAS versus patients who underwent CEA
(regardless of initial treatment assignment). Health status
scores were compared between the CAS and CEA groups
using analysis of covariance for continuous variables and
ordinal logistic regression for categorical variables, adjusting
for symptomatic status and baseline scores. In addition, to
account for the effect of ascertainment bias (in case patients
with more severe periprocedural stroke or MI were unable
to provide adequate health status data), these analyses were
repeated after imputing “worst case scores” to patients with
periprocedural events who had missing health status data
during follow-up.
For the exploratory analyses of the impact of clinical
events on HRQOL, only periprocedural events were con-
sidered because there was not a systematic attempt to
capture late MI, and rates of late stroke and late MI were
extremely low and similar between treatment groups during
longer-term follow-up. For each HRQOL outcome, we
used multiple linear regression to estimate the independent
change associated with the events of interest (stroke, MI,
cranial nerve palsy) while adjusting for age, sex, diabetes
mellitus, history of cardiovascular disease, and symptomatic
status at randomization.
For all analyses, a p value 0.05 was considered statisti-
cally significant; no adjustments were performed for multi-
ple comparisons. All analyses were performed using SAS
software version 9.1 (SAS Institute, Cary, North Carolina).
Results
Patient population and key clinical outcomes. Between
December 2000 and July 2008, 2,502 patients were ran-
domly assigned to either CAS (n  1,262) or CEA (n 
1,240). Mean age was 69 years, 65% of patients were male,
the overwhelming majority of patients had at least 1
cardiovascular risk factor, and 85% of carotid stenoses
were at least 70% in severity. Overall, 47% of patients were
asymptomatic. As previously reported, rates of the primary
composite endpoint were similar for CAS and CEA (7.2%
and 6.8%, respectively; p  0.51) (15). Periprocedural
stroke was more common with CAS (4.1% vs. 2.3%, p 
0.01), and periprocedural MI was more common with CEA
(2.3% vs. 1.1%, p  0.03). Cranial nerve palsy was noted in
0.3% and 4.7% of the CAS and CEA patients, respectively
(p  0.01).
HRQOL outcomes. The CAS and CEA groups had
similar response rates for the HRQOL assessments both at
baseline and during follow-up (85% to 90% among surviv-
ing patients at all timepoints) (Fig. 1). Results from the
analyses of the general health status outcomes are summa-
rized in Table 1 and Figure 2.
At baseline, all SF-36 subscale scores were similar for the
2 groups. Compared with the CEA group, CAS patients
had better scores at 2 weeks for 5 of the 8 SF-36 subscales
(all p 0.01), with the role physical subscale demonstrating
the greatest difference between treatment groups. By
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scores in the CAS group, and there were no significant
differences for any of the SF-36 subscales at 1 year. Findings
were unchanged when multiple imputation was used to
account for missing data (Online Table 1), when the
analyses were repeated according to treatment received
(Online Table 2), or when using “worst case scores” for
missing health status data among patients experiencing
periprocedural events (Online Tables 3 and 4).
Results for the disease-specific Likert scales are summa-
rized in Figures 3 and 4. At 2 weeks, CAS patients reported
less difficulty eating or swallowing, less difficulty driving,
and less impairment from headaches and neck pain as
compared with CEA patients. However, CAS patients also
reported more difficulty walking and more impairment from
Figure 1 Completeness of Data
Available health status data for patients randomly assigned to carotid artery
stent (CAS) versus carotid endarterectomy (CEA). Percentages listed above
each bar indicate the proportion of surviving patients with health status scores
available at that timepoint. Red area of bar indicates eligible with data; green
area of bar indicates eligible with no data.
Baseline Health Status Scores and Differences Between CAS VersuDuring Follow-Up Af er Adjusting for Symptomatic Status and BaseTable 1 Baseline Health St tus cor s and Differences BetweeDuring Follow-Up After Adjusting for Symptomatic Stat
Baseline Scores
SF-36 Subscale (Raw Data) CAS CEA
Physical function 61.5 29.2 63.5 28.3
Role–physical 44.6 43.3 46.4 43.8
Vitality 54.8 23.2 55.6 22.9
Pain index 64.2 27.7 66.0 26.7
Social function 73.0 27.3 73.8 27.2
General health 62.0 21.1 62.8 20.7
Role–emotional 69.1 40.7 69.2 41.4
Mental health 74.1 19.3 74.1 19.3
Physical component summary 39.9 11.6 40.8 11.2
Mental component summary 50.4 10.9 50.3 10.8Values are mean  SD or mean (95% confidence interval). *p  0.01 for the comparison of CAS versus
CAS  carotid artery stenting; CEA  carotid endarterectomy; SF-36  Medical Outcomes Study Shortleg pain. By the 1-month follow-up visit, CAS patients
continued to experience less difficulty eating or swallowing
and less impairment from headaches and neck pain, but
more limitations from leg pain than patients in the CEA
group. There were no significant differences in any of the
other disease-specific measures at 1 month, and no differ-
ences between the groups for any measure by the 12-month
assessment. These results were unchanged when multiple
imputation was used to account for missing data (Online
Figs. 1 and 2), or for the on-treatment analysis (Online
Figs. 3 and 4).
For ratings of overall pain on a 0 to 10 scale, CAS and
CEA patients reported similar scores at baseline (mean
score 3.1 vs. 3.0, p 0.23). At the 2-week assessment, CAS
patients reported significantly lower pain scores than CEA
patients (mean 2.9 vs. 3.1, p  0.01), but these differences
were no longer present by the 1-month assessment (mean
3.0 vs. 3.1, p  0.16) and the 12-month assessment (mean
3.0 vs. 3.0, p  0.86). Similarly, CAS patients reported less
need for pain medications during the week preceding the
2-week assessment (odds ratio: 0.64 vs. CEA patients,
confidence interval: 0.54 to 0.76, p  0.01), but there was
no difference between the groups at the 1-month evaluation
(odds ratio: 1.01, 95% confidence interval: 0.85 to 1.21, p
0.90) or 12-month evaluation (odds ratio: 1.06, 95% confi-
dence interval: 0.88 to 1.27, p  0.57).
Impact of periprocedural stroke and MI events on
HRQOL. The results of the exploratory analyses to esti-
mate the impact of periprocedural events on 1-year health
status domains are summarized in Table 2. Patients who
had a periprocedural stroke reported worse HRQOL scores
at 1 year for 7 of 8 domains of the SF-36 when compared
with patients who had no periprocedural events. In contrast,
periprocedural MI was associated with worse general health
perception at 1 year, but no differences in any other health
status domains. Cranial nerve palsy was not associated with
a sustained impact on HRQOL.
AcoresS V rsus CEA
d Baseline Scores
Difference During Follow-Up CAS Versus CEA
2 Weeks 1 Month 12 Months
2.2 (0.6 to 3.9)* 2.3 (0.5 to 4.1)† 0.8 (1.2 to 2.9)
8.7 (5.7 to 11.7)* 8.3 (5.1 to 11.6)* 2.0 (1.7 to 5.6)
3.5 (1.7 to 5.3)* 0.9 (0.7 to 2.5) 0 (1.7 to 1.7)
3.0 (1.0 to 5.0)* 1.4 (0.5 to 3.2) 0.2 (1.9 to 2.2)
3.3 (1.3 to 5.3)* 2.5 (0.6 to 4.5)† 1.2 (0.9 to 3.2)
0.9 (2.3 to 0.5) 0 (1.3 to 1.4) 0.1 (1.4 to 1.7)
0.4 (2.9 to 3.7) 0.9 (2.2 to 4.0) 1.1 (4.4 to 2.2)
1.1 (0.4 to 2.5) 0.5 (0.8 to 1.8) 0.4 (0.9 to 1.8)
1.6 (0.9 to 2.3)* 1.4 (0.7 to 2.1)* 0.4 (0.5 to 1.2)
0.5 (0.3 to 1.4) 0.2 (0.6 to 1.0) 0 (0.8 to 0.8)s CEline Sn A
us anCEA. †p  0.05 for the comparison of CAS versus CEA.
-Form 36.
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Trend in Medical Outcomes Study Short-Form 36 (SF-36) scores from baseline to 1 year. Higher scores indicate better quality of life; significant differences in
scores (p  0.01) were noted in 5 of 8 subscales and the physical component summary scale at the 2-week follow-up visit, and in 3 of 8 subscales and the
physical component summary scale at the 1-month follow-up visit. All differences between groups had resolved by 1 year. Plotted values at each timepoint repre-
sent least-squares means and associated 95% confidence intervals derived from the analysis of covariance. CAS  red; CEA  blue. Abbreviations as in Figure 1.
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In this pre-specified substudy of the CREST study, we
found that patients undergoing CAS had better HRQOL
during the first month after carotid revascularization relative
to patients undergoing CEA. These benefits were most
pronounced for measures of overall physical function and
pain. In addition, disease-specific measures demonstrated
that limitations related to ambulation and leg discomfort
were more common after CAS, whereas limitations related
to eating and neck discomfort were more common after
Figure 3 Disease-Specific Functional Limitations
Trend in modified Likert scores from baseline to 1 year for (A) difficulty eating
or swallowing, (B) difficulty walking, and (C) difficulty driving. Green  mild
difficulty; yellow  moderate difficulty, red  severe difficulty, and black 
unable. Abbreviations as in Figure 1.CEA. All of these differences between CAS and CEA weremodest in magnitude and were no longer present at 1-year
follow-up.
Exploratory analyses of the impact of periprocedural
events on health status revealed a strong and consistent
impairment of HRQOL at 1 year among those patients who
experienced a periprocedural stroke when compared with
patients who did not. For most scales, these differences
exceeded values generally considered to be clinically mean-
ingful. In contrast, there was minimal or no long-term
impairment in health status among patients who had a
periprocedural MI or cranial nerve palsy. To date, this is the
largest study comparing recovery patterns among patients
Figure 4 Disease-Specific Pain Scales
Trend in modified Likert scores from baseline to 1 year for (A) headaches,
(B) neck pain, and (C) leg pain. Green  “a little bit,” yellow  “moderately,”
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events on HRQOL after carotid revascularization.
These results are consistent with previous results from 1
nonrandomized evaluation of CAS and CEA (20), and are also
similar to findings from the SAPPHIRE (Stenting and An-
gioplasty With Protection in Patients at High Risk for End-
arterectomy) randomized clinical trial (6). In the quality of life
substudy of the SAPPHIRE study, patients reported fewer
symptoms and less impairment of physical function at the
2-week visit when undergoing CAS versus CEA, but these
differences were no longer apparent at 1 month (21). The
present analysis from the CREST study demonstrated some-
what greater functional status benefits of CAS over CEA at 2
weeks, and in contrast to the SAPPHIRE study, these differ-
ences were largely maintained at the 1-month follow-up visit
for both generic and disease-specific assessments.
There are several potential explanations for the differ-
ences between the CREST study and the SAPPHIRE
study results. First, the CREST study enrolled nearly 8
times as many patients as the SAPPHIRE study, and the
additional quality of life differences in the CREST study
may simply reflect its greater statistical power. Alternatively,
the differences between trials may be explained by differ-
ences in patient populations, as patients in the SAPPHIRE
trial had a greater burden of comorbidity due to the enrollment
requirement of high surgical risk. As a result, the healthier
patient population in the CREST study may have experi-
enced a more benign recovery period, which would allow
differences in health status after CAS versus CEA to be
more readily detected. Regardless of the underlying mech-
anisms, HRQOL outcomes were similar for the 2 treatment
groups during longer-term follow-up for both the CREST
study and SAPPHIRE study populations.
In addition to the pre-specified analyses comparing CAS
versus CEA, we performed post-hoc analyses to explore in
greater depth the impact of early events on late health status.
These exploratory analyses demonstrated that health status




(95% CI) p Value
Physical function 14.2 (20.7 to7.8) 0.001
Role–physical 23.3 (34.4 to12.1) 0.001
Vitality 11.0 (16.3 to5.7) 0.001
Pain index 7.6 (14.1 to1.1) 0.021
General health 4.3 (9.1 to 0.5) 0.080
Social function 7.0 (13.5 to0.6) 0.033
Role–emotional 25.1 (35.4 to14.7) 0.001
Mental health 5.5 (9.8 to1.2) 0.013
Physical component summary 4.4 (7.0 to1.8) 0.001
Mental component summary 4.1 (6.6 to1.7) 0.001
*Mean difference between patients with or without each periprocedural event after adjustment fo
and symptomatic status before carotid revascularization.
Abbreviations as in Table 1.at 1 year was influenced by the occurrence of periprocedural tstroke, but not by either MI or cranial nerve palsy. These
findings are not particularly surprising. Most studies of
stroke have found persistent disability in 15% to 30% of
surviving patients (30,31), which would be expected to
result in impaired physical function, role function, and
general health perception. In contrast, after the initial
short-term recovery phase, patients with MI generally have
health status that is similar to the general population unless
the MI is large and associated with clinical heart failure or
a protracted recovery period (32,33). Notwithstanding the
results of our analysis, MI should not be construed as a
benign event as it has been associated with a poor long-term
prognosis in multiple settings (34–36).
Conversely, the lack of association between cranial nerve
palsy and quality of life was somewhat unexpected, as 5%
ave been reported to be persistent after CEA in previous
tudies (with rates ranging from 3% to 23%) (37). The
ffects of cranial nerve injury can be quite variable, however,
anging from complete facial palsy to mild paresthesias of
he tongue. It is also possible that the SF-36 was insensitive
o the degree of disability and HRQOL impairment caused
y cranial nerve palsies in the CREST study population.
It may seem counterintuitive that overall health status
nd quality of life did not differ after CAS or CEA despite
he higher rate of stroke after CAS and the significant
mpact of stroke on 1-year HRQOL in the study popula-
ion. It is important to note, however, that the vast majority
f patients (95% in both treatment groups) did not
xperience a stroke—thus limiting the impact of such events
n any between-group measures of HRQOL. Indeed, a trial
owered to detect a 0.5 point difference in role physical
unction (the expected between-group difference based on
he CREST study results) would require randomization of
200,000 patients.
Although 1-year HRQOL did not differ between the
AS and CEA groups, some patients may favor 1 or the
ther approach to carotid revascularization according to
w-Upt 1-Year Follow-Up
Myocardial Infarction Cranial Nerve Palsy
Mean Difference*
(95% CI) p Value
Mean Difference*
(95% CI) p Value
5.8 (14.5 to 3.0) 0.196 1.5 (4.7 to 7.6) 0.643
2.4 (17.6 to 12.7) 0.752 3.9 (6.7 to 14.6) 0.471
4.6 (11.8 to 2.5) 0.205 4.6 (0.5 to 9.7) 0.075
7.0 (1.8 to 15.8) 0.120 1.3 (7.5 to 5.0) 0.692
7.8 (14.3 to1.2) 0.020 1.9 (2.7 to 6.5) 0.429
2.4 (11.1 to 6.4) 0.598 3.2 (3.0 to 9.4) 0.307
0 (14.0 to 14.0) 0.999 0.8 (9.1 to 10.6) 0.881
3.0 (2.8 to 8.9) 0.308 3.0 (1.1 to 7.1) 0.157
2.0 (5.6 to 1.5) 0.260 0.1 (2.4 to 2.6) 0.939
0.5 (2.9 to 3.8) 0.787 1.4 (1.0 to 3.7) 0.263
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prevention is the principal indication for carotid revascular-
ization, many patients may prefer CEA over CAS, because
CEA minimizes the risk of such events. Conversely, pa-
tients at very low risk of periprocedural stroke (e.g., younger,
asymptomatic patients) may consider the more rapid recov-
ery and lesser health status impairment during the first
month after revascularization to be a compelling argument
for CAS.
Study limitations. As with any clinical trial, the results of
our study may not be generalizable to all patients who are
candidates for carotid revascularization. Nonetheless, the
large number of sites and operators included in the CREST
study suggests that our results should apply to many other
centers and operators who are able to meet the volume and
training criteria required for CREST study certification
(15,23). In addition, 10% of the CREST study patients
did not receive their assigned revascularization procedure,
mainly related to patients who were enrolled on the basis of
noninvasive carotid imaging and were subsequently found to
be anatomically unsuitable for CAS—many of whom then
underwent CEA. The effect of such treatment crossovers
would be expected to dilute any true treatment differences,
however, and the similarity of our intention-to-treat and
on-treatment results suggests that the extent of bias intro-
duced was small. Finally, some quality of life data were
missing at each follow-up timepoint. Nonetheless, the
response rates were quite high considering the patient
population, and it is reassuring that the results were un-
changed in analyses incorporating multiply imputed data.
Conclusions
Among patients with clinical indications and anatomy
suitable for either surgical or percutaneous carotid revascu-
larization, CAS was associated with better HRQOL during
the early recovery period as compared with CEA. These
differences were less pronounced at 1 month than at 2 weeks
and were no longer present after 1 year. Although stroke
was more common after CAS than after CEA and was
associated with clinically important health status impair-
ment throughout follow-up, the small absolute difference in
event rates did not result in a detectable difference in
long-term HRQOL between the 2 treatments. These
health status data, in conjunction with evidence (from
CREST and other trials) regarding the absolute and relative
risk of important clinical events, should help to better
inform patients and clinicians regarding the risks and
benefits of CAS versus CEA, and thus help guide patient-
centered decision making.
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